Product Program year 2020 Source: CMS Open Payments

Ameluz

Drug Dermatology

NDC 70621-101-01

Open in the dashboard

General payments

$385,390

4,508 payments

Research payments

$1,032,551

77 payments

Through program year 2020, $385,390 in general payments and $1,032,551 in research payments were reported against Ameluz (Dermatology).

No combined total These are different kinds of money, reported under different rules. A meal and a clinical trial grant do not add up to anything meaningful, so this site does not add them.

By program year

4 rows
Year Kind Amount Payments
2020 General $40,875 1,093
2020 Research $762,061 54
2019 General $344,515 3,415
2019 Research $270,490 23

Breakdown

Who paid General payments · program years 2019–2020
  1. Biofrontera Inc. $385,390 4,508 payments
Top recipients General payments · program year 2020
  1. Brent Moody MOHS-Micrographic Surgery · Nashville, TN $5,778 14% · 3 payments
  2. Daniel Siegel MOHS-Micrographic Surgery · Smithtown, NY $4,703 12% · 4 payments
  3. Mark Kaufmann Dermatology · New York, NY $4,570 11% · 3 payments
  4. Sadra Jazayeri Dermatology · Phoenix, AZ $4,000 10% · 1 payment
  5. Howard Rogers Dermatology · Norwich, CT $3,735 9% · 4 payments

The top 5 of the 100 largest recipients; each share is of general payments naming this product in 2020.

The top 25 recipients, free in the app

Specialties paid General payments · program year 2020
  1. Dermatology $26,274 66% · 583 practitioners
  2. MOHS-Micrographic Surgery Dermatology $11,602 29% · 56 practitioners
  3. Procedural Dermatology Dermatology $748 2% · 30 practitioners
  4. Family Medicine $357 <1% · 15 practitioners
  5. Dermatopathology Dermatology $297 <1% · 16 practitioners

The top 5 of 29 specialties; each share is of general payments naming this product to practitioners with a specialty in 2020. Each practitioner is counted under their primary specialty.

The top 25 specialties, free in the app

Where the money went General payments · program year 2020
  1. Florida $7,109 17% · 100 recipients
  2. New York $6,445 16% · 60 recipients
  3. Tennessee $6,087 15% · 16 recipients
  4. Arizona $4,209 10% · 6 recipients
  5. Connecticut $3,844 9% · 7 recipients

The top 5 of 43 states; each share is of general payments naming this product in 2020 where a state was reported.

The top 25 states, free in the app

Given in the clinic

Part B · billing code
Medicare Part B billing codes matched to Ameluz
Billing code Providers Services Paid by Medicare
Aminolevulinic acid hcl for topical administration, 10% gel, 10 mg J7345 815 7,885,670 $10,319,141

Drugs given by a clinician are billed to Medicare Part B, not Part D. The product is tied to a billing code through the NDC on CMS's crosswalk, which was published for a later quarter than the payments, so a code that changed in between can be missed. Providers with fewer than 11 patients for the code are not published. Medicare's payment here is what it paid for the services, to the billing practice.

4,508 general · 77 research

Every payment, record by record

Date, amount, who was paid and what for — filter by year and kind, or download as CSV, free, in files of 5,000 rows.

What you are looking at

Manufacturers name the drug, biological or device a payment relates to. CMS does not give products their own identifiers, so a product here is assembled from how it was reported — a brand may appear under more than one spelling, and this page covers one of them rather than the brand as a whole.

Provenance

Source: CMS Open Payments · through program year 2020

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record